Reneo Pharmaceuticals Inc (RPHM)
1.66
+0.06
(+3.75%)
USD |
NASDAQ |
May 16, 16:00
1.66
0.00 (0.00%)
After-Hours: 20:00
Reneo Pharmaceuticals Enterprise Value: -27.36M for May 16, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 16, 2024 | -27.36M |
| May 15, 2024 | -29.36M |
| May 14, 2024 | -28.69M |
| May 13, 2024 | -29.70M |
| May 10, 2024 | -22.34M |
| May 09, 2024 | -20.67M |
| May 08, 2024 | -21.67M |
| May 07, 2024 | -24.68M |
| May 06, 2024 | -25.02M |
| May 03, 2024 | -24.68M |
| May 02, 2024 | -25.02M |
| May 01, 2024 | -25.69M |
| April 30, 2024 | -27.02M |
| April 29, 2024 | -27.02M |
| April 26, 2024 | -27.02M |
| April 25, 2024 | -27.69M |
| April 24, 2024 | -26.69M |
| April 23, 2024 | -26.86M |
| April 22, 2024 | -26.35M |
| April 19, 2024 | -24.68M |
| April 18, 2024 | -24.01M |
| April 17, 2024 | -23.68M |
| April 16, 2024 | -27.69M |
| April 15, 2024 | -27.36M |
| April 12, 2024 | -25.02M |
| Date | Value |
|---|---|
| April 11, 2024 | -26.02M |
| April 10, 2024 | -25.69M |
| April 09, 2024 | -26.02M |
| April 08, 2024 | -26.69M |
| April 05, 2024 | -25.69M |
| April 04, 2024 | -25.02M |
| April 03, 2024 | -25.69M |
| April 02, 2024 | -25.69M |
| April 01, 2024 | -26.02M |
| March 28, 2024 | -47.48M |
| March 27, 2024 | -47.82M |
| March 26, 2024 | -47.82M |
| March 25, 2024 | -47.15M |
| March 22, 2024 | -47.48M |
| March 21, 2024 | -46.48M |
| March 20, 2024 | -47.48M |
| March 19, 2024 | -47.82M |
| March 18, 2024 | -48.15M |
| March 15, 2024 | -47.48M |
| March 14, 2024 | -49.49M |
| March 13, 2024 | -49.16M |
| March 12, 2024 | -49.49M |
| March 11, 2024 | -49.16M |
| March 08, 2024 | -47.48M |
| March 07, 2024 | -48.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-90.72M
Minimum
May 23 2022
270.24M
Maximum
May 07 2021
22.83M
Average
2.473M
Median
Enterprise Value Benchmarks
| Mirum Pharmaceuticals Inc | 1.171B |
| NovaBay Pharmaceuticals Inc | 5.209M |
| Palatin Technologies Inc | 23.43M |
| iBio Inc | 16.17M |
| Theriva Biologics Inc | -8.844M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -8.426M |
| Total Expenses (Quarterly) | 9.564M |
| EPS Diluted (Quarterly) | -0.25 |
| Earnings Yield | -131.3% |